Many medical conditions lead to a constant need for chronic opioid medication. Clinical trials of new opioid drugs have multiple study design and operational challenges. For example, opioid diversion is a frequently encountered and complex problem that can vary by country, investigational sites, study participants, and study staff. Proactive risk planning and mitigation therefore become extremely important. Dr Lynne Hughes, Vice President at Quintiles, discusses lessons learned from executing these clinical trials.